Agenus | AGEN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 6.57B 2.82B 2026-06
Agenus USD 18.74M 16.26M 2026-06
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Celldex Therapeutics USD 47.45M 11.72M 2026-06
CSL USD 2.16B 633M 2025-06
Eli Lilly USD 8.95B 3.67B 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
Intrexon USD 9.34M 1.77M 2024-06
J&J USD 20.42B 1.27B 2026-06
Jiangsu Hengrui CNY 40.53B 428.6M 2026-03
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
MacroGenics USD 113.91M 47.39M 2026-06
Merck EUR 2.74B 415M 2026-03
Merck USD 6.85B 1.52B 2026-06
Northwest Biotherapeutics USD 4.56M 244K 2025-09
Novartis USD 7.62B 739M 2026-06
Novavax USD 191.46M 36.9M 2026-06
Pfizer USD 976M 727M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Veracyte USD 299.52M 36.38M 2026-06